Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases

Journal of Neuro-Oncology

Volumn 118, Issue 1, 2014, Pages 109-116

  Queirolo, Paola ^a   Spagnolo, Francesco ^a   Ascierto, Paolo Antonio ^b   Simeone, Ester ^b   Marchetti, Paolo ^c,d   Scoppola, Alessandro ^c   Del Vecchio, Michele ^e   Di Guardo, Lorenza ^e   Maio, Michele ^f   Di Giacomo, Anna Maria ^f   Antonuzzo, Andrea ^g   Cognetti, Francesco ^h   Ferraresi, Virginia ^h   Ridolfi, Laura ⁱ   Guidoboni, Massimo ⁱ   Guida, Michele ^j   Pigozzo, Jacopo ^k   Chiarion Sileni, Vanna ^k  

^a UNIVERSITY OF GENOA   (Italy)

^b NATIONAL CANCER INSTITUTE   (Italy)

^c LABORATORIO DI PATOLOGIA VASCOLARE   (Italy)

^d SAPIENZA UNIVERSITY OF ROME   (Italy)

^e NATIONAL CANCER INSTITUTE   (Italy)

^f UNIVERSITY HOSPITAL OF SIENA   (Italy)

^g UNIVERSITY HOSPITAL OF PISA   (Italy)

^h REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

ⁱ DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^j NATIONAL CANCER INSTITUTE GIOVANNI PAOLO II   (Italy)

^k VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

more..

Author keywords

Brain metastases; Expanded access; Ipilimumab; Melanoma; Safety; Treatment outcome

Indexed keywords

IPILIMUMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; ASTHENIA; ASYMPTOMATIC DISEASE; BRAIN METASTASIS; CANCER CHEMOTHERAPY; CANCER CONTROL; CLINICAL TRIAL (TOPIC); CONFUSION; DIARRHEA; DRUG EFFICACY; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; FEASIBILITY STUDY; FEMALE; FEVER; HEADACHE; HUMAN; INOPERABLE CANCER; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; NAUSEA; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; PRURITUS; RASH; RETROSPECTIVE STUDY; VOMITING; BRAIN NEOPLASMS; FOLLOW UP; KAPLAN MEIER METHOD; MIDDLE AGED; PATHOLOGY; SECONDARY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTIBODIES, MONOCLONAL; BRAIN NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOLOGIC FACTORS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84901633374     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1400-y     Document Type: Article

References (35)

1. Fife KM, Colman MH, Stevens GN, Firth IC, Moon D, Shannon KF, Harman R, Petersen-Schaefer K, Zacest AC, Besser M, Milton GW, McCarthy WH, Thompson JF (2004) Determinants of outcome in melanoma patients with cerebral metastases. J Clin Oncol 22:1293-1300 (Pubitemid 41079844)
2. Sloan AE, Nock CJ, Einstein DB (2009) Diagnosis and treatment of melanoma brain metastasis: a literature review. Cancer Control 16:248-255
3. Majer M, Jensen RL, Shrieve DC, Watson GA, Wang M, Leachman SA, Boucher KM, Samlowski WE (2007) Biochemotherapy of metastatic melanoma in patients with or without recently diagnosed brain metastases. Cancer 110:1329-1337 (Pubitemid 47435606)
4. Staudt M, Lasithiotakis K, Leiter U, Meier F, Eigentler T, Bamberg M, Tatagiba M, Brossart P, Garbe C (2010) Determinants of survival in patients with brain metastases from cutaneous melanoma. Br J Cancer 102:1213-1218. doi:10.1038/sj.bjc.6605622
5. Bhangoo SS, Linskey ME, Kalkanis SN, American Association of Neurologic Surgeons (AANS), Congress of Neurologic Surgeons (CNS) (2011) Evidence-based guidelines for the management of brain metastases. Neurosurg Clin N Am 22:97-104, viii. doi:10.1016/j.nec.2010.09.001
6. McWilliams RR, Brown PD, Buckner JC, Link MJ, Markovic SN (2003) Treatment of brain metastases from melanoma. Mayo Clin Proc 78:1529-1536 (Pubitemid 37475636)
7. Gerstner ER, Fine RL (2007) Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. J Clin Oncol 25:2306-2312
8. Yonemori K, Tsuta K, Ono M, Shimizu C, Hirakawa A, Hasegawa T, Hatanaka Y, Narita Y, Shibui S, Fujiwara Y (2010) Disruption of the blood brain barrier by brain metastases of triple-negative and basal-type breast cancer but not HER2/neu-positive breast cancer. Cancer 116:302-308. doi:10.1002/cncr.24735
9. Dummer R, Goldinger S, Turtschi C, Eggmann N, Michielin O, Mitchell L, Veronese L, Hilfiker PR, Rinderknecht JD (2012) Open-label pilot study of vemurafenib in previously treated metastatic melanoma patients with symptomatic brain metastases. Ann Oncol 23(9 Suppl):1125P
10. Long GV, Trefzer U, Davies MA, Kefford RF, Ascierto PA, Chapman PB, Puzanov I, Hauschild A, Robert C, Algazi A, Mortier L, Tawbi H, Wilhelm T, Zimmer L, Switzky J, Swann S, Martin AM, Guckert M, Goodman V, Streit M, Kirkwood JM, Schadendorf D (2012) Dabrafenib in patients with Val600Glu or Val600Lys BRAF-mutant melanoma metastatic to the brain (BREAK-MB): a multicentre, open-label, phase 2 trial. Lancet Oncol 13:1087-1095. doi:10.1016/S1470-2045(12)70431-X
11. Hoos A, Ibrahim R, Korman A, Abdallah K, Berman D, Shahabi V, Chin K, Canetta R, Humphrey R (2010) Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin Oncol 37:533-546. doi:10.1053/j. seminoncol.2010.09.015
12. YERVOY™ Summary of Product Characteristics. http://www.medicines. org.uk/emc/medicine/24779/SPC/yervoy%205%20mg* ml%20concentrate%20for%20solution%20for%20infusion/#INDICATIONS. Accessed on 6 Jan 2014
13. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, Akerley W, van den Eertwegh AJ, Lutzky J, Lorigan P, Vaubel JM, Linette GP, Hogg D, Ottensmeier CH, Lebbé C, Peschel C, Quirt I, Clark JI, Wolchok JD, Weber JS, Tian J, Yellin MJ, Nichol GM, Hoos A, Urba WJ (2010) Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 363:711-723. doi:10.1056/NEJMoa1003466
14. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, Lebbe C, Baurain JF, Testori A, Grob JJ, Davidson N, Richards J, Maio M, Hauschild A, Miller WH Jr, Gascon P, Lotem M, Harmankaya K, Ibrahim R, Francis S, Chen TT, Humphrey R, Hoos A, Wolchok JD (2011) Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 364:2517-2526. doi:10.1056/ NEJMoa1104621
15. Lebbe C, Weber JS, Maio M, Neyns B, Harmankaya K, Chin K, Opatt McDowell D, Cykowski L, McHenry MB, Wolchok JD (2012) Five-year survival rates for patients with metastatic melanoma treated with ipilimumab in phase II trials. Ann Oncol 23(9 Suppl):1116PD
16. Prieto PA, Yang JC, Sherry RM, Hughes MS, Kammula US, White DE, Levy CL, Rosenberg SA, Phan GQ (2012) CTLA-4 blockade with ipilimumab: long-term follow-up of 177 patients with metastatic melanoma. Clin Cancer Res 18:2039-2047. doi:10.1158/1078-0432.CCR-11-1823
17. Ibrahim RA, Berman DM, DePril V, Humphrey RW, Chen T, Messina M, Chin KM, Liu HY, Bielefield M, Hoos A (2011) Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. J Clin Oncol 29(15 Suppl):8583
18. Weber J (2007) Review: anti-CTLA-4 antibody ipilimumab: case studies of clinical response and immune-related adverse events. Oncologist 12:864-872
19. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, Richards J, Michener T, Balogh A, Heller KN, Hodi FS (2012) Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncol 13:459-465. doi:10.1016/S1470-2045(12)70090-6
20. Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, Fonsatti E, Annesi D, Queirolo P, Testori A, Ridolfi R, Parmiani G, Maio M (2012) Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncol 13:879-886. doi:10.1016/S1470-2045(12) 70324-8
21. Weber JS, Amin A, Minor D, Siegel J, Berman D, O'Day SJ (2011) Safety and clinical activity of ipilimumab in melanoma patients with brain metastases: retrospective analysis of data from a phase 2 trial. Melanoma Res 21:530-534. doi:10.1097/CMR.0b013e32834d3d88
22. Lebbe C, McDermott DF, Robert C, Lorigan P, Ottensmeier CH, Wolchok J, Garbe C, Messina M, Hoos A, Weber JS (2010) Ipilimumab improves survival in previously treated, advanced melanoma patients with poor prognostic factors: subgroup analyses from a phase III trial. Ann Oncol 21(8 Suppl):13240
23. Heller K, Pavlick AC, Hodi FS, Thompson JA, Margolin KA, Lawrence DP, McDermott DF, Samlowski WE, Michener T, Karasarides M (2011) Safety and survival analysis of ipilimumab therapy in patients with stable asymptomatic brain metastases. J Clin Oncol 29(15 Suppl):8581
24. Engelhardt B, Coisne C (2011) Fluids and barriers of the CNS establish immune privilege by confining immune surveillance to a two-walled castle moat surrounding the CNS castle. Fluids Barriers CNS 8:4. doi:10.1186/2045-8118-8-4
25. Wilson EH, Weninger W, Hunter CA (2010) Trafficking of immune cells in the central nervous system. J Clin Invest 120:1368-1379. doi:10.1172/JCI41911
26. Queirolo P, Simeone E, De Galitiis F, Di Guardo L, Di Giacomo AM, Marconcini R, Ferraresi V, De Rosa F, Guida M, Stragliotto S (2012) Efficacy and safety data from patients with advanced melanoma and brain metastases participating in the European ipilimumab Expanded Access Programme in Italy. Ann Oncol 23(9 Suppl):1132P
27. Wolchok JD, Hoos A, O'Day S, Weber JS, Hamid O, Lebbé C, Maio M, Binder M, Bohnsack O, Nichol G, Humphrey R, Hodi FS (2009) Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res 15:7412-7420. doi:10.1158/1078-0432.CCR-09-1624
28. Lawrence D, McDermott D, Hamid O, Weber JS, Wolchok J, Richards J, Minor D, Pavlick A, Sznol M, Hwu P, Urba W, Amin A, Bennett K, Michener T, Balogh A, Hodi F (2012) Treatment of patients with stage III or IV melanoma on an ipilimumab Expanded Access Program: results for 3 mg/kg cohort. Pigment Cell Melanoma Res 25(6):868
29. Maio M, Bondarenko I, Robert C, Thomas L, Garbe C, Testori A, Francis S, Chin K, Wolchok J (2012) Four-year survival update for metastatic melanoma patients treated with ipilimumab plus dacarbazine in phase 3 study CA184-024. Ann Oncol 23(9 Suppl):1127P
30. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, Siegel J, O'Day SJ (2009) A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumab administered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clin Cancer Res 15:5591-5598. doi:10.1158/1078-0432.CCR-09-1024
31. Tarhini A, Lo E, Minor DR (2010) Releasing the brake on the immune system: ipilimumab in melanoma and other tumors. Cancer Biother Radiopharm 25:601-613. doi:10.1089/cbr 2010.0865
32. Hinrichs CS, Palmer DC, Rosenberg SA, Restifo NP (2005) Glucocorticoids do not inhibit antitumor activity of activated CD8 + T cells. J Immunother 28:517-524 (Pubitemid 41533084)
33. Ackerman A, McDermott DF, Lawrence DP, Gunturi A, Flaherty KT, Giobbie-Hurder A, Hodi FS, Ibrahim N, Atkins MB, Cho DC, Sullivan RJ (2012) Outcomes of patients with malignant melanoma treated with immunotherapy prior to or after vemurafenib. J Clin Oncol 30(15 Suppl):8569
34. Ascierto PA, Simeone E, Giannarelli D, Grimaldi AM, Romano A, Mozzillo N (2012) Sequencing of BRAF inhibitors and ipilimumab in patients with metastatic melanoma: a possible algorithm for clinical use. J Transl Med 10:107. doi:10.1186/1479-5876-10-107
35. Ascierto PA, Chiarion Sileni V, Del Vecchio M, Altomonte M, De Galitiis F, Ridolfi L, Cognetti F, Testori A, Bernengo MG, Queirolo P (2012) The European ipilimumab Expanded Access Programme: efficacy and safety data from the Italian cohort of patients with pretreated, advanced melanoma. Ann Oncol 23(9 Suppl):1128P